AVAKI: Three Customers to Accelerate Drug Discovery with its 2.1 SW

CAMBRIDGE, MA -- AVAKI Corporation, a pioneer in global grid software solutions, today announced three leading drug discovery organizations have licensed AVAKI 2.1, the first comprehensive, commercially-available software to combine both compute and data grid capabilities into a single product. Gene Logic Inc., Infinity Pharmaceuticals and Structural Bioinformatics, Inc. (SBI), will use AVAKI's technology to provide shared access to critical data and applications and improve the utilization of information technology resources. As a result, these companies can speed their data and analytic products to market helping to accelerate the drug discovery process.